EFSA Supporting PublicationsVolume 12, Issue 1 739E External scientific reportOpen Access Strategy support for the Post-Market Monitoring (PMM) of GM plants: Review of existing PMM strategies developed for the safety assessment of human and animal health ADAS UK ltd, ADAS UK ltdSearch for more papers by this author ADAS UK ltd, ADAS UK ltdSearch for more papers by this author First published: 26 January 2015 https://doi.org/10.2903/sp.efsa.2015.EN-739Citations: 2 The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors. Published date: 26 January 2015 Question number: EFSA-Q-2013-00701 AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References Abenhaim L Moore N Begaud B, 1999. The role of pharmacoepidemiology in pharmacovigilance: A conference at the 6th ESOP Meeting, Budapest, 28 September 1998. Pharmacoepidemiology and Drug Safety, 8, S1– S7. Agorastos T Chatzigeorgiou K Brotherton JML Garland SM, 2009. Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far. Vaccine, 27, 7270– 7281. Ahmad SR, 2003. Adverse drug event monitoring at the Food and Drug Administration – Your report can make a difference. Journal of General Internal Medicine, 18, 57– 60. Alberman E, 1986. Post-marketing surveillance of oral contraceptives. Human Reproduction, 1, 433– 434. Alemayehu D Andrews EN Glue P Knirsch CA, 2010. Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting. PLoS Neglected Tropical Diseases, 4. Alger HM Maffini MV Kulkarni NR Bongard ED Neltner T, 2013. Perspectives on how FDA Assesses Exposure to Food Additives When Evaluating Their Safety: Workshop proceedings. Comprehensive Reviews in Food Science and Food Safety, 12, 90– 119. Allgood GS Kuter DJ Roll KT Taylor SL Zorich NL, 2001. Postmarketing surveillance of new food ingredients: Results from the program with the fat replacer olestra. Regulatory Toxicology and Pharmacology, 33, 224– 233. Amarasinghe A Black S Bonhoeffer J Carvalho SMD Dodoo A Eskola J Larson H Shin S Olsson S Balakrishnan MR Bellah A Lambach P Maure C Wood D Zuber P Akanmori B Bravo P Pombo M Langar H Pfeifer D Guichard S Diorditsa S Hossain MS Sato Y, 2013. Effective vaccine safety systems in all countries: A challenge for more equitable access to immunization. Vaccine, 31, B108– B114. Anon., 1983. Monitoring of drugs after marketing. The Journal of the Royal College of General Practitioners, 33, 438– 441. Anon., 2005. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice. Federal register, 70, 16827– 16828. Anon., 2007. The Erice Manifesto: for global reform of the safety of medicines in patient care. Drug safety : an international journal of medical toxicology and drug experience, 30, 187– 190. Anon., 2012. Pharmacovigilance and communicating safety information. Drug and therapeutics bulletin, 50, 138– 140. ANSES (Agence nationale de sécurité sanitairede l'alimentation, de l'environnement et du travail), 2013. Individual and national study on food consumption. https://www.anses.fr/en/content/individual-and-national-study-food-consumption-inca-study. Arimura K Nakagawa M Izumo S Usuku K Itoyama Y Kira J-I Osame M, 2007. Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy. Journal of Neurovirology, 13, 364– 372. Arlett PR Kurz X, 2011. New approaches to strengthen pharmacovigilance. Drug Discovery Today: Technologies, 8, e15– e19. Balkrishnan R Furberg CD, 2001. Developing an optimal approach to global drug safety. Journal of Internal Medicine, 250, 271– 279. Bandekar MS Anwikar SR Kshirsagar NA, 2010. Quality check of spontaneous adverse drug reaction reporting forms of different countries. Pharmacoepidemiology and Drug Safety, 19, 1181– 1185. Banerjee AK Okun S Edwards IR Wicks P Smith MY Mayall SJ Flamion B Cleeland C Basch E, 2013. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance. Drug Safety, 36, 1129– 1149. Barnes J, 2003. Pharmacovigilance of herbal medicines – A UK perspective. Drug Safety, 26, 829– 851. Bast A Chandler RF Choy PC Delmulle LM Gruenwald J Halkes SBA Keller K Koeman JH Peters P Przyrembel H De Ree EM Renwick AG Vermeer ITM, 2002. Botanical health products, positioning and requirements for effective and safe use. Environmental Toxicology and Pharmacology, 12, 195– 211. Beck-Peccoz P Minuto F Leal-Cerro A Zabransky M Stalla G, 2012. Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with growth hormone deficiency. Therapeutic Advances in Endocrinology and Metabolism, 3, 85– 91. Begaud B Moride Y Tubertbitter P Chaslerie A Haramburu F, 1994. FALSE-POSITIVES IN SPONTANEOUS REPORTING – SHOULD WE WORRY ABOUT THEM. British Journal of Clinical Pharmacology, 38, 401– 404. Bencheikh RS Benabdallah G, 2009. Medication errors: pharmacovigilance centres in detection and prevention. British Journal of Clinical Pharmacology, 67, 687– 690. Bennett CL Nebeker JR Lyons EA Samore MH Feldman MD McKoy JM Carson KR Belknap SM Trifilio SM Schumock GT Yarnold PR Davidson CJ Evens AM Kuzel TM Parada JP Cournoyer D West DP Sartor O Tallman MS Raisch DW, 2005. The Rresearch on Adverse Drug Events and Reports (RADAR) project. Jama-Journal of the American Medical Association, 293, 2131– 2140. Bennett CL Nebeker JR Yarnold PR Tigue CC Dorr DA McKoy JM Edwards BJ Hurdle JF West DP Lau DT Angelotta C Weitzman SA Belknap SM Djulbegovic B Tallman MS Kuzel TM Benson AB Evens A Trifilio SM Courtney DM Raisch DW, 2007. Evaluation of serious adverse drug reactions: A Proactive Pharmacovigilance Program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Archives of Internal Medicine, 167, 1041– 1049. Bergman U, 1992. Second thoughts. Pharmacoepidemiological Perspectives. Journal of Clinical Epidemiology, 45, 313– 317. Berlin JA Glasser SC Ellenberg SS, 2008. Adverse event detection in drug development: Recommendations and obligations beyond phase 3. American Journal of Public Health, 98, 1366– 1371. Berne B Tammela M Färm G Inerot A Lindberg M, 2008. Can the reporting of adverse skin reactions to cosmetics be improved? A prospective clinical study using a structured protocol. Contact Dermatitis, 58, 223– 227. Bhosale VV Gaur SPS, 2011. Adverse drug reaction monitoring. Current Science, 101, 1024– 1027. Bian J Topaloglu U Yu F, 2012. Towards large-scale twitter mining for drug-related adverse events. 25– 32. Blake KV Smeraldi C Kurz X Arlett P Blackburn S Fitt H, 2011. The European network of centres for pharmacoepidemiology and pharmacovigilance: Application to diabetes and vascular disease. British Journal of Diabetes and Vascular Disease, 11, 304– 307. BMEL (Bundesministerium für Ernährung und Landwirtschaft), 2009. National Nutrition Survey Two. http://www.was-esse-ich.de/index.php?id=44 Bond RA, 2006. A proposal for a national program reporting beneficial drug responses, analogous to the existing program to detect adverse drug responses. Medical Hypotheses, 66, 10– 13. Bons B Audebert F Bitaudeau C Cachin N Colson L Farr C Fix LA Gilmour N Gorni R Griffiths M Harris B Holle V Kirk S Meredith E Pari C Poinsot P Renner G, 2010. Assessment of undesirable events in cosmetic market surveillance: Background, description and use of a causality assessment method in cosmetovigilance. Regulatory Toxicology and Pharmacology, 58, 349– 353. Bousquet PJ Demoly P Romano A Aberer W Bircher A Blanca M Brockow K Pichler W Torres MJ Terreehorst I Arnoux B Atanaskovic-Markovic M Barbaud A Bijl A Bonadonna P Burney PG Caimmi S Canonica GW Cernadas J Dahlen B Daures JP Fernandez J Gomes E Gueant JL Kowalski ML Kvedariene V Mertes PM Martins P Nizankowska-Mogilnicka E Papadopoulos N Ponvert C Pirmohamed M Ring J Salapatas M Sanz ML Szczeklik A Van Ganse E De Weck AL Zuberbier T Merk HF Sachs B Sidoroff A, 2009. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GA2LEN platform. The Galenda project. Allergy: European Journal of Allergy and Clinical Immunology, 64, 194– 203. Breckenridge A, 2008. Post-marketing strategies for medicines [1]. Clinical Pharmacology and Therapeutics, 83, 24– 25. Bren L, 2003. FDA's response to food, dietary supplement, and cosmetic adverse events. FDA Consumer, 37. Brewer T Colditz GA, 1999. Postmarketing surveillance and adverse drug reactions current perspectives and future needs. Journal of the American Medical Association, 281, 824– 829. Bright RA Nelson RC, 2002. Automated support for pharmacovigilance: a proposed system. Pharmacoepidemiology and Drug Safety, 11, 121– 125. Buchbinder R March L Lassere M Briggs AM Portek I Reid C Meehan A Henderson L Wengier L Van Den Haak R, 2007. Effect of treatment with biological agents for arthritis in Australia: The Australian Rheumatology Association Database. Internal Medicine Journal, 37, 591– 600. Burk M Moore V Glassman P Good CB Emmendorfer T Leadholm TC Cunningham F, 2013. Medication-use evaluation with a Web application. American Journal of Health-System Pharmacy, 70, 2226– 2234. Butchko HH Kotsonis FN, 1991. Acceptable daily intake vs actual intake: The aspartame example. Journal of the American College of Nutrition, 10, 258– 266. Butchko HH Tschanz C Kotsonis FN, 1994. Postmarketing surveillance of food additives. Regulatory Toxicology and Pharmacology, 20, 105– 118. Butler SF Budman SH Licari A Cassidy TA Lioy K Dickinson J Brownstein JS Benneyan JC Green TC Katz N, 2008. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™): A real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiology and Drug Safety, 17, 1142– 1154. Caster O Norén GN Madigan D Bate A, 2010. Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database. Statistical Analysis and Data Mining, 3, 197– 208. Castle GH Kelly B, 2008. Global harmonization is not all that global: Divergent approaches in drug safety. Food and Drug Law Journal, 63, 601– 622+i. Chazard E Ficheur G Bernonville S Luyckx M Beuscart R, 2011. Data Mining to Generate Adverse Drug Events Detection Rules. Ieee Transactions on Information Technology in Biomedicine, 15, 823– 830. Chee BW Berlin R Schatz B, 2011. Predicting adverse drug events from personal health messages. AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium, 2011, 217– 226. Cicero TJ Dart RC Inciardi JA Woody GE Schnoll S Munoz A, 2007. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS (R)). Pain Medicine, 8, 157– 170. Clark DWJ Coulter DM Besag FMC, 2008. Randomized controlled trials and assessment of drug safety. Drug Safety, 31, 1057– 1061. Coloma PM Trifiro G Patadia V Sturkenboom M, 2013. Postmarketing Safety Surveillance Where does Signal Detection Using Electronic Healthcare Records Fit into the Big Picture? Drug Safety, 36, 183– 197. Cook MN, 2006. Estimating national drug consumption using data at different points in the pharmaceutical supply chain. Pharmacoepidemiology and Drug Safety, 15, 754– 757. Crowther M, 2013. Phase 4 research: what happens when the rubber meets the road? Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2013, 15– 18. Curtis LH Weiner MG Boudreau DM Cooper WO Daniel GW Nair VP Raebel MA Beaulieu NU Rosofsky R Woodworth TS Brown JS, 2012. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiology and Drug Safety, 21, 23– 31. Czarnecki A Maciejczyk A, 1997. Pharmacovigilance in Poland. Pharmacoepidemiology and Drug Safety, 6, 277– 281. Dal Pan GJ, 2014. Ongoing Challenges in Pharmacovigilance. Drug Safety, 37, 1– 8. Dart RC, 2009. Monitoring risk: Post marketing surveillance and signal detection. Drug and Alcohol Dependence, 105, S26– S32. Dasgupta N Schnoll SH, 2009. Signal detection in post-marketing surveillance for controlled substances. Drug and Alcohol Dependence, 105, S33– S41. Davis RL Kolczak M Lewis E Nordin J Goodman M Shay DK Platt R Black S Shinefield H Chen RT, 2005. Active surveillance of vaccine safety: A system to detect early signs of adverse events. Epidemiology, 16, 336– 341. De Vries ST Mol PGM de Zeeuw D Haaijer-Ruskamp FM Denig P, 2013. Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire. Drug Safety, 36, 765– 777. Defra (Department for Environment, Food & Rural Affairs), 2014 Latest animal feed production statistics. https://www.gov.uk/government/statistics/animal-feed-production. DeStefano F Vaccine Safety Datalink Res G, 2001. The Vaccine Safety Datalink project. Pharmacoepidemiology and Drug Safety, 10, 403– 406. Dieck GS Sharrar RG, 2013. Preparing for safety issues following drug approval: Pre-approval risk management considerations. Therapeutic Advances in Drug Safety, 4, 220– 228. Dikshit RK Desai C Desai MK, 2008. Pleasures and pains of running a pharmacovigilance center. Indian Journal of Pharmacology, 40, S31– S34. Dogra R Garg R Kumar V Verma V Tripathi V, 2013. Detection, assessment, understanding and prevention of adverse effects: Pharmacovigilance: A review. International Journal of Pharmaceutical Sciences Review and Research, 20, 71– 86. Du W Lehr VT Lieh-Lai M Koo W Ward RM Rieder MJ Van Den Anker JN Reeves JH Mathew M Lulic-Botica M Aranda JV, 2013. An Algorithm to Detect Adverse Drug Reactions in the Neonatal Intensive Care Unit. Journal of Clinical Pharmacology, 53, 87– 95. Dunn N Mann RD, 1999. Prescription-event and other forms of epidemiological monitoring of side-effects in the UK. Clinical and Experimental Allergy, 29, 217– 239. EuroFIR, 2014. EuroFIR website. http://www.eurofir.org/?page_id=3 Edwards IR, 1998. Safety monitoring of new anti-malarials in immediate post-marketing phase. Medecine tropicale : revue du Corps de sante colonial, 58, 93– 96. Edwards IR, 2000. Spontaneous ADR reporting and drug safety signal induction in perspective – To honour Professor Jens Schou. Pharmacology & Toxicology, 86, 16– 19. Edwards IR, 2012. Pharmacovigilance. British Journal of Clinical Pharmacology, 73, 979– 982. Edwards R Faich G Tilson H, 2005. Points to consider: the roles of surveillance and epidemiology in advancing drug safety. Pharmacoepidemiology and Drug Safety, 14, 665– 667. EFSA (European Food Safety Authority), 2011. The food classification and description system FoodEx 2. http://www.efsa.europa.eu/en/supporting/pub/215e.htm. EFSA (European Food Safety Authority), 2014. EU Menu. http://www.efsa.europa.eu/en/datexfoodcdb/datexeumenu.htm. Egberts ACG Meyboom RHB van Puijenbroek EP, 2002. Use of measures of disproportionality in pharmacovigilance – Three Dutch examples. Drug Safety, 25, 453– 458. Egberts TCG, 2007. Signal detection: Historical background. Drug Safety, 30, 607– 609. Eguale T Tamblyn R Winslade N Buckeridge D, 2008. Detection of adverse drug events and other treatment outcomes using an electronic prescribing system. Drug Safety, 31, 1005– 1016. Eguale T Winslade N Hanley JA Buckeridge DL Tamblyn R, 2010. Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: A Validation study in Canada. Drug Safety, 33, 559– 567. EPIC (European Prospective Investigation into Cancer and Nutrition), 2014. EPIC study webpage. http://epic.iarc.fr/ Evans JMM MacDonald TM, 1999. Record-linkage for pharmacovigilance in Scotland. British Journal of Clinical Pharmacology, 47, 105– 110. Faden LB Milne C-P, 2008. Pharmacovigilance activities in the United States, European Union and Japan: Harmonic convergence or convergent evolution? Food and Drug Law Journal, 63, 683– 700. Faich G Morris J, 2012. Adverse Reaction Signaling and Disproportionality Analysis: An Update. Drug Information Journal, 46, 708– 714. Fan K Sun X Tao Y Xu L Wang C Mao X Peng B Pan Y, 2010. High-Performance Signal Detection for Adverse Drug Events using MapReduce Paradigm. AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium, 2010, 902– 906. Farrington P Pugh S Colville A Flower A Nash J Morgancapner P Rush M Miller E, 1995. A new method for active surveillance of adverse events from diphtheria-tetanus-pertussis and measles mumps rubella vaccines. Lancet, 345, 567– 569. Feedipedia, 2013. Link to Feedipedia website homepage. http://www.feedipedia.org/ Fernandopulle RBM Weerasuriya K, 2003. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world. Drug Safety, 26, 219– 225. Fischer T, Maibech H, 1984. Finn chamber patch test technique. Contact Dermatitis, 11, 137– 140. Fleuranceau-Morel P, 2002. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Pharmacoepidemiology and Drug Safety, 11, 37– 44. Fox B, 2012. Closing the information gap: Informing better medical decisionmaking through the use of post-market safety and comparative effectiveness information. Food and Drug Law Journal, 67, 83– 101+iii. Fram DM Almenoff JS Dumouchel W, 2003. Empirical Bayesian data mining for discovering patterns in post-marketing drug safety. 359– 368. Frauger E Moracchini C Le Boisselier R Braunstein D Thirion X Micallef J French C-AN, 2013. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundamental & Clinical Pharmacology, 27, 672– 682. FSA (Food Standards Agency), 2010. Background to the composition of foods review. http://tna.europarchive.org/20110116113217/http://www.food.gov.uk/science/dietarysurveys/dietsurveys/backgrdcofr Fujiwara Y Kobayashi K, 2002. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). Critical Reviews in Oncology Hematology, 42, 145– 155. Gagne JJ Glynn RJ Rassen JA Walker AM Daniel GW Sridhar G Schneeweiss S, 2012. Active Safety Monitoring of Newly Marketed Medications in a Distributed Data Network: Application of a Semi-Automated Monitoring System. Clinical Pharmacology & Therapeutics, 92, 80– 86. Gagne JJ Rassen JA Walker AM Glynn RJ Schneeweiss S, 2012. Active safety monitoring of new medical products using electronic healthcare data: Selecting alerting rules. Epidemiology, 23, 238– 246. Ghosh AK De A Bala NN, 2011. Current problems and future aspects of pharmacovigilance in India. International Journal of Pharma and Bio Sciences, 2, 15– 28. Gogtay NJ Dalvi SS Kshirsagar NA, 2003. Safety monitoring: An Indian perspective. International Journal of Risk and Safety in Medicine, 16, 21– 30. Griffin MR Braun MM Bart KJ, 2009. What Should an Ideal Vaccine Postlicensure Safety System Be? American Journal of Public Health, 99, S345– S350. Haerian K Varn D Vaidya S Ena L Chase HS Friedman C, 2012. Detection of Pharmacovigilance-Related Adverse Events Using Electronic Health Records and Automated Methods. Clinical Pharmacology & Therapeutics, 92, 228– 234. Hall RF, 2007. The risk of risk reduction: Can postmarket surveillance pose more risk than benefit? Food and Drug Law Journal, 62, 473– 492. Harpaz R Vilar S DuMouchel W Salmasian H Haerian K Shah NH Chase HS Friedman C, 2013. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. Journal of the American Medical Informatics Association, 20, 413– 419. Hepburn P Boeing H Cockburn A Constable A Davi A Howlett J de Jong N Moseley B Oberdorfer R Robertson C Verhagen H Wal J-M, 2006. Utility of post-market monitoring of novel foods. Toxicology Letters, 164, S49– S49. Hilmer SN Gnjidic D Abernethy DR, 2012. Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults. Journals of Gerontology Series a-Biological Sciences and Medical Sciences, 67, 181– 188. Hoffmann A Hippius M Sicker T, 1998. Adverse drug reaction monitoring in Jena – experiences of a regionalized pharmacovigilance centre. Experimental and Toxicologic Pathology, 50, 453– 457. Howlett J Edwards DG Cockburn A Hepburn P Kleiner J Knorr D Kozianowski G Mueller D Peijnenburg A Perrin I Poulsen M Walker R, 2003. The safety assessment of novel foods and concepts to determine their safety in use. International Journal of Food Sciences and Nutrition, 54, S1– S32. Hugman B, 2005. From the Uppsala Monitoring Centre: A review of Viewpoint part 1 and part 2. Drug Safety, 28, 645– 646. Inman WHW, 1981. Postmarketing surveillance of adverse drug reactions in general practice. I. Search for new methods. British Medical Journal, 282, 1131– 1132. Iragueen D Urcelay S Martin BS, 2011. Pharmacovigilance in veterinary medicine in Chile: a pilot study. Journal of Veterinary Pharmacology and Therapeutics, 34, 108– 115. Isah AO Pal SN Olsson S Dodoo A Bencheikh RS, 2012. Specific features of medicines safety and pharmacovigilance in Africa. Therapeutic Advances in Drug Safety, 3, 25– 34. Ishaq GM Shah MY Koul PA Tanki SA, 2004. Adverse drug reaction monitoring with a Kashmiri perspective – Need for an urgent initiative. JK Practitioner, 11, 85– 87. James C, 2012. Global status of commercialized biotech/GM crops: ISAAA Brief 44. Johansson S Wallander MA De Abajo FJ Rodríguez LAG, 2010. Prospective drug safety monitoring using the UK primary-care general practice research database: Theoretical framework, feasibility analysis and extrapolation to future scenarios. Drug Safety, 33, 223– 232. Juarez-Olguin H Perez-Guille G Flores-Perez J, 2007. Pharmacovigilance and pharmacoepidemiology of drugs in a Mexican pediatric hospital. A proposed guide. Pharmacy World & Science, 29, 43– 46. KantarWorldpanel, 2014. Webpages on consumer panels. http://www.kantarworldpanel.com/global/Consumer-Panels Kapp JF Zentgraf R Widmer A Schopf E, 1991. A NEED TO INTENSIFY DRUG SURVEILLANCE IN GERMANY. Klinische Wochenschrift, 69, 775– 779. Karande S Gogtay NJ Kshirsagar NA, 2003. Improving drug safety monitoring. Indian pediatrics, 40, 1167– 1175. Kelman C, 2010. Pharmacology Researcher Biographical Sketches and Research Summaries. An Australian model for a national medicines monitoring system. Z Mihaylov and G Stoyanov, (eds) Nova science publishers. 205– 206 Khairnar A Gade PR, 2011. Interventional improvement in hospital based intensive monitoring of adverse event. Research Journal of Pharmacy and Technology, 4, 1443– 1448. Khattri S Balamuralidhara V Pramod KTM Valluru R Venkatesh MP, 2012. Pharmacovigilance regulations in India: A Step forward. Clinical Research and Regulatory Affairs, 29, 41– 45. Kim JH, Scialli AR, 2011. Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicological Sciences, 122, 1– 6. Kingston R, 2005. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements. Thrombosis Research, 117, 137– 144. Kristal AR Vizenor NC Patterson RE Neuhouser ML Shattuck AL McLerran D, 2000. Precision and bias of food frequency-based measures of fruit and vegetable intakes. Cancer Epidemiology Biomarkers & Prevention, 9, 939– 944. Kubota K, 1999. A design for Prescription-Event Monitoring in Japan (J-PEM). Pharmacoepidemiology and Drug Safety, 8, 447– 456. Layton D Hazell L Shakir SAW, 2011. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug safety : an international journal of medical toxicology and drug experience, 34, e1– 9. Lea LJ Hepburn PA, 2006. Safety evaluation of phytosterol-esters. Part 9. Results of a European post-launch monitoring programme. Food Chem Toxicol, 44, 1213– 1222 Mahmood KT Amin F Tahir MUl Haq I, 2011. Pharmacovigilance – A need for best patient care in Pakistan. A review. Journal of Pharmaceutical Sciences and Research, 3, 1566– 1584. Mann RD, 1998. Prescription-event monitoring – recent progress and future horizons. British Journal of Clinical Pharmacology, 46, 195– 201. Markowitz LE Hariri S Unger ER Saraiya M Datta SD Dunne EF, 2010. Post-licensure monitoring of HPV vaccine in the United States. Vaccine, 28, 4731– 4737. Martinez-Frias ML, 2007. Postmarketing analysis of medicines – Methodology and value of the Spanish case-control study and surveillance system in preventing birth defects. Drug Safety, 30, 307– 316. Mazzitello C Esposito S De Francesco A Capuano A Russo E De Sarro G, 2013. Pharmacovigilance in Italy: An overview. Journal of Pharmacology and Pharmacotherapeutics, 4, S20– S28. McClure DL Glanz JM Xu S Hambidge SJ Mullooly JP Baggs J, 2008. Comparison of epidemiologic methods for active surveillance of vaccine safety. Vaccine, 26, 3341– 3345. McClure DL Raebel MA Yih WK Shoaibi A Mullersman JE Anderson-Smits C Glanz JM, 2014. Mini-Sentinel methods: Framework for assessment of positive results from signal refinement. Pharmacoepidemiology and Drug Safety, 23, 3– 8. McNeil JJ Grabsch EA McDonald MM, 1999. Postmarketing surveillance: Strengths and limitations. The flucloxacillin-dicloxacillin story. Medical Journal of Australia, 170, 270– 273. McNeil JJ Piccenna L Ronaldson K Ioannides-Demos LL, 2010. The value of patient-centred registries in phase IV drug surveillance. Pharmaceutical Medicine, 24, 281– 288. Mehta U Dheda M Steel G Blockman M Ntilivamunda A Maartens G Pillay Y Cohen K, 2014. Strengthening pharmacovigilance in South Africa. South African Medical Journal, 104, 104– 106. Mönkemeyer W Schmidt, K, 2014. Use of farmer/producer associations/federations to form sentinel surveillance networks for adverse effects in primary production. http://www.efsa.europa.eu/it/search/doc/543e.pdf Montastruc JL Sommet A Lacroix I Olivier P Durrieu G Damase-Michel C Lapeyre-Mestre M Bagheri H, 2006. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine, 73, 629– 632. Montastruc JL, Sommet A, Bagheri H, & Lapeyre-Mestre M, 2011. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. British Journal of Clinical Pharmacology, 72, 905– 908. Monteiro SAMG Takano OA Waldman EA, 2011. Evaluation of the Brazilian survei